| A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma JW Kjeldsen, CL Lorentzen, E Martinenaite, E Ellebaek, M Donia, ... Nature medicine 27 (12), 2212-2223, 2021 | 91 | 2021 |
| The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy MO Holmström, E Martinenaite, SM Ahmad, Ö Met, C Friese, L Kjær, ... Leukemia 32 (2), 429-437, 2018 | 81 | 2018 |
| Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? HC Hasselbalch, MO Holmström Seminars in Immunopathology 41 (1), 5-19, 2019 | 65 | 2019 |
| The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms MO Holmström, CH Riley, IM Svane, HC Hasselbalch, MH Andersen Leukemia 30 (12), 2413-2416, 2016 | 64 | 2016 |
| The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms MO Holmström, MD Hjortsø, SM Ahmad, Ö Met, E Martinenaite, C Riley, ... Leukemia 31 (2), 495-498, 2017 | 57 | 2017 |
| Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma
MO Holmström, P Gimsing, N Abildgaard, NF Andersen, C Helleberg, ... American journal of hematology 90 (4), E73-4, 2015 | 57 | 2015 |
| JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation J Czech, S Cordua, B Weinbergerova, J Baumeister, A Crepcia, L Han, ... Leukemia 33 (4), 995-1010, 2019 | 55 | 2019 |
| Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment L Kjær, S Cordua, MO Holmström, M Thomassen, TA Kruse, N Pallisgaard, ... PloS one 11 (10), e0165336, 2016 | 50 | 2016 |
| The Danish national multiple myeloma registry P Gimsing, MO Holmström, TW Klausen, NF Andersen, H Gregersen, ... Clinical epidemiology, 583-587, 2016 | 38 | 2016 |
| The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy SM Ahmad, E Martinenaite, M Holmström, MA Jørgensen, Ö Met, ... Oncoimmunology 7 (2), e1390641, 2018 | 33 | 2018 |
| High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals MO Holmström, SM Ahmad, U Klausen, SK Bendtsen, E Martinenaite, ... Blood cancer journal 9 (2), 8, 2019 | 32 | 2019 |
| Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic
J Handlos Grauslund, MO Holmström, NG Jørgensen, U Klausen, ... Frontiers in Oncology 11, 637420, 2021 | 31 | 2021 |
| Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage
MO Holmström, CH Riley, V Skov, IM Svane, HC Hasselbalch, ... Oncoimmunology 7 (6), e1433521, 2018 | 30 | 2018 |
| Frequent adaptive immune responses against arginase-1 E Martinenaite, REJ Mortensen, M Hansen, M Orebo Holmström, ... Oncoimmunology 7 (3), e1404215, 2018 | 27 | 2018 |
| Novel strategies for peptide-based vaccines in hematological malignancies U Klausen, S Holmberg, MO Holmström, NGD Jørgensen, JH Grauslund, ... Frontiers in immunology 9, 2264, 2018 | 24 | 2018 |
| Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients ME Bjørn, MO Holmström, HC Hasselbalch Leukemia & Lymphoma 57 (1), 125-128, 2016 | 21 | 2016 |
| Cancer immune therapy for Philadelphia chromosome-negative chronic myeloproliferative neoplasms MO Holmström, HC Hasselbalch, MH Andersen Cancers 12 (7), 1763, 2020 | 20 | 2020 |
| Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes L Kjaer, MO Holmström, S Cordua, MH Andersen, IM Svane, ... Leukemia & lymphoma 59 (4), 973-977, 2018 | 20 | 2018 |
| Cancer immune therapy for myeloid malignancies: present and future MO Holmström, HC Hasselbalch Seminars in Immunopathology 41 (1), 97-109, 2019 | 19 | 2019 |
| Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer MO Holmström, S Cordua, V Skov, L Kjær, N Pallisgaard, C Ellervik, ... Cancer Immunology, Immunotherapy 69, 315-324, 2020 | 18 | 2020 |
